TG Therapeutics TGTX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's total liabilities?
- TG Therapeutics (TGTX) reported total liabilities of $945.71M in Q1 2026.
- How has TG Therapeutics's total liabilities changed year-over-year?
- TG Therapeutics's total liabilities increased by 125.5% year-over-year, from $419.4M to $945.71M.
- What is the long-term trend for TG Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), TG Therapeutics's total liabilities has grown at a 31.3% compound annual growth rate (CAGR), from $106.29M to $415.23M.
- What does total liabilities mean?
- The total amount of money the company owes to all creditors and lenders.
- How do you interpret total liabilities?
- An increase suggests higher financial leverage or debt accumulation, while a decrease indicates debt repayment or reduced obligations.
- How does total liabilities compare across companies?
- Varies significantly by industry; biotech companies typically maintain lower liabilities compared to capital-intensive manufacturing firms.